 The National Medical Products Administration NMPA has approved Antengene Corporation Limiteds Investigational New Drug Application for a Phase 1 trial of ATG-019 in China. The trial will evaluate the safety and tolerability of ATG-019 monotherapy or combined with niacin ER in patients with advanced solid tumors or non-Hodgkins lymphoma NHL. 